RegulatoryCompany release
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
China's NMPA has cleared two applications for oral sovleplenib, covering adults with chronic primary immune thrombocytopenia and warm antibody autoimmune haemolytic anaemia.
HUTCHMED announced on 19 November 2026 that China's National Medical Products Administration (NMPA) has approved two new drug applications for SYVIK (sovleplenib), an oral spleen tyrosine kinase (Syk) inhibitor. The two approvals were granted at the same time.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): HUTCHMED (China) Ltd ↗
Article written by VigiEye from the official source (HUTCHMED (China) Ltd). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
Portugal's CNFT updates antibiotic guidance for hospitals and primary care, stressing stewardship links
🇵🇹 INFARMED · Thu 19 Nov 2026
UK confirms plan to widen gene therapy definition to cover synthetic and genome-editing products
🇬🇧 MHRA · Thu 19 Nov 2026
MHRA to legislate on revised gene therapy definition after strong consultation support
🇬🇧 MHRA · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 190/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends veterinary, phytosanitary and technical regulation annexes in Decision No 194/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026